Article
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance.
Proceedings of the National Academy of Sciences of the United States of America - 20 Dec 2011
Powdrill Megan H, Tchesnokov Egor P, Kozak Robert A, Russell Rodney S, Martin Ross, Svarovskaia Evguenia S, Mo Hongmei, Kouyos Roger D, Götte Matthias
Abstract excerpt
The development of resistance to direct-acting antivirals (DAAs) targeting the hepatitis C virus (HCV) can compromise therapy. However, mechanisms that determine prevalence and frequency of resistance-conferring mutations remain elusive. Here, we studied the fidelity of the HCV RNA-dependent RNA polymerase NS5B in an attempt to link the efficiency of mismatch formation with genotypic changes observed in vivo....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
